

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

BRISTOL-MYERS SQUIBB COMPANY and	)	
PFIZER INC.,	)	
	)	
Plaintiffs and Counterclaim-Defendants	)	
	)	
v.	)	C.A. No. 17-374-LPS
	)	(CONSOLIDATED)
AUROBINDO PHARMA USA INC. and	)	
AUROBINDO PHARMA LTD.,	)	
	)	
Defendants and Counterclaim-Plaintiffs.	)	


BRISTOL-MYERS SQUIBB COMPANY	)	
and PFIZER INC.,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	C.A. No. 17-379-LPS
	)	
MYLAN PHARMACEUTICALS INC.,	)	
	)	
Defendant.	)	

**ORDER**

At Wilmington, this **18th** day of **October, 2018**:

For the reasons set forth in the Memorandum Opinion issued on this date,

**IT IS HEREBY ORDERED** that Defendant Mylan Pharmaceuticals Inc.’s Motion to Dismiss or Transfer Under 28 U.S.C. § 1406(a) for Improper Venue (C.A. No. 17-379 D.I. 178) is **GRANTED**. **IT IS FURTHER ORDERED** that the parties shall meet and confer and, no later than **October 22, 2018**, submit a joint status report and any necessary or requested order to implement today’s decision.

  
 UNITED STATES DISTRICT JUDGE